Potential of an LRG1-Targeting Degrader in Combating Aggressive Triple-Negative Breast Cancer
ACS Omega · 12.11.2026
DOI: 10.1021/acsomega.6c07595 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Omega, online erschienen am 12.11.2026. Verfasst von Yating Wang und 8 weiteren Autor:innen. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Henan Provincial Science and Technology Research Project.
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) remains clinically challenging due to its aggressive phenotype and the scarcity of druggable targets. Leucine-rich alpha-2-glycoprotein 1 (LRG1) is a critical driver of TNBC progression, yet its has precluded the development of conventional occupancy-driven inhibitors. In this study, we employed an event-driven proteolysis-targeting chimera (PROTAC) strategy to target this “undruggable” LRG1 for degradation. Leveraging our previously developed ETTAC-2─a peptide-based PROTAC with established efficacy in ocular neovascularization and renal fibrosis models─we demonstrate that this degrader induces effective LRG1 degradation via the ubiquitin-proteasome system in a dose- and time-dependent manner in 4T1 TNBC cells. Mechanistically, ETTAC-2-mediated degradation of LRG1 suppressed the p-AKT and HIF-1α signaling axes, impairing cell proliferation in vitro and orchestrating a robust antitumor response in vivo. Systemic administration of ETTAC-2 significantly attenuated mammary tumor growth and impeded the aggressive phenotype by reversing the epithelial-mesenchymal transition (EMT) program through sustained inhibition of HIF-1α signaling. By effectively reversing EMT markers and curtailing the malignant progression of TNBC without observable systemic toxicity, our findings validate LRG1 as a viable therapeutic target and establish ETTAC-2 as a pioneering lead compound that bypasses structural limitations to treat recalcitrant breast cancers.
Förderung
- Henan Provincial Science and Technology Research Project
Zitieren
APA
Wang, Y., Zhu, F., Li, Y., Li, Y., Song, S., Zhu, X., Min, H., Li, Y., & Qi, Y. (2026). Potential of an LRG1-Targeting Degrader in Combating Aggressive Triple-Negative Breast Cancer. ACS Omega. https://doi.org/10.1021/acsomega.6c07595
Vancouver
Wang Y, Zhu F, Li Y, Li Y, Song S, Zhu X, et al. Potential of an LRG1-Targeting Degrader in Combating Aggressive Triple-Negative Breast Cancer. ACS Omega. 2026. doi:10.1021/acsomega.6c07595
BibTeX
@article{Wang2026,
author = {Wang, Yating and Zhu, Furong and Li, Yongzheng and Li, Yu and Song, Shiyu and Zhu, Xiaoming and Min, Huan and Li, Yao and Qi, Yingqiu},
title = {Potential of an LRG1-Targeting Degrader in Combating Aggressive Triple-Negative Breast Cancer},
journal = {ACS Omega},
year = {2026},
doi = {10.1021/acsomega.6c07595}
}
EUVIMED